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ABSTRACT
Despite the approval of numerous molecular targeted drugs, long-term 
antiproliferative efficacy is rarely achieved and therapy resistance remains a central 
obstacle of cancer care. Combined inhibition of multiple cancer-driving pathways promises 
to improve antiproliferative efficacy. HIF-1 is a driver of gastric cancer and considered to be 
an attractive target for therapy. We noted that gastric cancer cells are able to functionally 
compensate the stable loss of HIF-1α. Via transcriptomics we identified a group of 
upregulated genes in HIF-1α-deficient cells and hypothesized that these genes confer 
survival upon HIF-1α loss. Strikingly, simultaneous knock-down of HIF-1α and Annexin A1 
(ANXA1), one of the identified genes, resulted in complete cessation of proliferation. Using 
stable isotope-resolved metabolomics, oxidative and reductive glutamine metabolism was 
found to be significantly impaired in HIF-1α/ANXA1-deficient cells, potentially explaining 
the proliferation defect. In summary, we present a conceptually novel application of 
stable gene inactivation enabling in-depth deconstruction of resistance mechanisms. In 
theory, this experimental approach is applicable to any cancer-driving gene or pathway 
and promises to identify various new targets for combination therapies.
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INTRODUCTION
Ever since the advent of the post-genomic era, our 
understanding of the molecular pathogenesis of cancer 
has increased tremendously. Modern technology has 
enabled accurate and detailed analyses of the molecular 
mechanisms and signalling networks that govern basic 
malignant traits such as proliferation, metastasis and 
therapy resistance. Clinical translation of these analyses 
resulted in the approval of a plethora of molecular-targeted 
drugs in the last decade. Unfortunately, the general 
efficacy of molecular-targeted drugs could not fulfill the 
enormous expectations that accompanied their approval 
[1]. We propose, as others have done before us, that the 
emergence of resistant tumor cell subpopulations during 
molecular-targeted therapy results in therapy failure and, 
ultimately, disease progression [1–4]. In order to develop 
agents for combinatorial or sequential targeted therapy 
it is of pivotal importance to characterize underlying 
resistance-mediating mechanisms [5]. Here, we introduce 
an experimental approach how to exploit the functional 
inactivation of an oncoprotein, in this case the hypoxia-
inducible factor-1 (HIF-1), to identify molecules and 
pathways that govern resistance and would hence qualify 
as targets for an effective combination therapy.
The transcription factor HIF-1 was initially 
characterized as an important mediator of cellular 
adaptation to hypoxia [6]. Reduced oxygen levels impose 
vigorous metabolic demands on cells and HIF- 1 is an 
essential regulator of the metabolic changes that occur 
in response to hypoxia [7, 8]. Of note, biologically 
relevant stabilization of HIF-1 under normoxic conditions 
can be achieved in different settings and has led to the 
recognition of hypoxia-independent functions of HIF-1 
[7, 9]. The observation that HIF-1 is expressed by a vast 
number of different human cancers and their metastases, 
the anti-proliferative effect of HIF-1 inhibition on tumor 
growth in vitro and in vivo, and the pivotal importance 
of hypoxia/HIF-1 for chemo- and radioresistance have 
led to the appreciation of HIF-1 as an attractive target for 
cancer therapy [7, 10–12]. As outlined above, application 
of targeted drugs is accompanied by rapid development 
of therapy resistance. Against this background, we 
hypothesized that HIF-1 inhibitors will also be challenged 
by drug resistance and, subsequently, loss of clinical 
efficacy [7]. This is supported by the fact that cells 
harbouring a stable, shRNA-mediated inactivation of 
HIF-1α, the oxygen-regulated subunit of HIF-1, often do 
not show a significant growth defect in vitro compared to 
wildtype cells [13–15]. We and others have previously 
reported the crucial dependence of human gastric cancer 
progression on the functional integrity of HIF-1 [15–19]. 
Hence, gastric cancer would be a reasonable entity for 
HIF-1 inhibitors and we decided to use established human 
gastric cancer cell lines to perform an in-depth analysis of 
the functional consequences of HIF-1α inhibition.
RESULTS
Functional compensation of stable HIF-1α 
inhibition
We have previously reported a highly efficient 
functional inactivation of HIF-1α in the gastric cancer cell 
lines AGS and MKN28 via lentiviral transduction of small 
hairpin RNAs (shRNA) (Supplementary Figure 1A and 1B) 
[15, 20]. Functional characterization of these cells 
identified HIF-1α as pivotal for the malignant phenotype 
of gastric cancer [15, 20, 21]. Against this background 
we were intrigued to note that anchorage-dependent 
proliferation of AGS and MKN28 cells was unaffected 
by stable loss of HIF-1α (Figure 1A and 1B). Moreover, 
growth of HIF-1α-deficient (HIF-) MKN28 xenografts 
was not significantly different from HIF-1α-proficient cells 
(scrambled control (SCR)) (Supplementary Figure 1C). 
HIF-2α has been shown to compensate for the loss of HIF-
1α [22], leading us to analyze HIF-2α protein stabilization 
via immunoblot. As no effect was detectable under 
normoxia and only a slight increase of HIF-2α protein 
expression was detectable under hypoxia, we concluded 
that HIF- 2α was not centrally involved in our experimental 
setup (Supplementary Figure 1D). To better understand 
the molecular consequences of the loss of HIF-1α we 
characterized the cellular transcriptome. Reassuringly, 
the results confirmed HIF1A as one of the most efficiently 
down-regulated genes in AGS HIF- compared to AGS 
SCR cells (Supplementary Figure 2A). Interestingly, a 
large group of genes were found up-regulated in AGS 
HIF- cells when compared to SCR cells (Supplementary 
Figure 2B). Given the central importance of HIF-1 for the 
malignant phenotype of AGS cells, the stable knock-down 
of HIF-1α can be expected to exert significant pressure 
on the cells to compensate for the loss of HIF-1α. We 
hypothesized that some of the genes that were found up-
regulated in HIF- cells are mediating this compensation. 
To prove this hypothesis we further analyzed Annexin A1 
(ANXA1), one of the genes significantly up-regulated in 
HIF- cells (Supplementary Figure 2B). This choice was 
primarily based on our previous work showing reduced 
NF-kB activity in AGS HIF- cells [21]. ANXA1 is a 
known inhibitor of NF-kB and might therefore explain 
reduced NF-kB activity upon HIF-1α loss [23]. We first 
confirmed enhanced ANXA1 expression via immunoblot 
(Figure 1C) and quantitative real-time PCR (qPCR, 
Supplementary Figure 3A). Immunocytochemistry 
revealed that the majority of ANXA1 localized to the 
nucleus of HIF-1α-deficient AGS cells (Supplementary 
Figure 3B). Annexin A1 (ANXA1) belongs to the annexin 
superfamily of calcium and phospholipid binding proteins 
[24]. While ANXA1 expression is inducible by hypoxia in 
a HIF-1-dependent fashion, a functional role for ANXA1 
under conditions of HIF-1 depletion has not been reported 
thus far [25]. Via chromatin immunoprecipitation (ChIP) 
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we analyzed activating chromatin marks, pan-acetylation 
of histone H4 and tri-methylation of lysine 4 of histone 
H3 (H3K4) at the ANXA1 promoter of AGS SCR and 
HIF-  cells. ChIP revealed an increase in pan-acetylation 
of histone H4 and tri-methylation of H3K4 in the promoter 
region of HIF- cells compared to SCR cells (Figure 1D). 
In addition, binding of the histone acetyltransferase p300 
to the ANXA1 promoter was observed, suggesting p300 
being responsible for increased acetylation. Increased 
transcriptional activity of the ANXA1 promoter was 
further indicated by recruitment of RNA polymerase II 
(Figure 1D). These data argue for an involvement of 
epigenetic mechanisms for the regulation of ANXA1 
transcription upon HIF-1α loss.
Simultaneous knock-down of HIF-1α and ANXA1 
resembles induced essentiality
To explore the cellular response upon combined 
inhibition of HIF-1α and ANXA1, we established a 
stable inhibition of ANXA1 in HIF- and SCR cells via 
lentiviral RNAi. Efficacy of the ANXA1 knock-down 
(KD) was shown by immunoblot (Figure 2A). Strikingly, 
simultaneous KD of HIF-1α and ANXA1 (HIF-/
ANXA- ) resulted in near complete cessation of both 
anchorage-dependent and –independent proliferation 
while inhibition of ANXA1 alone remained without 
effect in AGS cells (Figure 2B and 2C, Supplementary 
Figure 4A– 4D). While inhibition of HIF-1α or ANXA1 
alone did not result in relevant apoptosis, combined 
inhibition strongly enhanced both pre-G1 fraction 
(Supplementary Figure 5A–5D) and caspase-3 activation 
(Figure 2D). In addition, robust induction of senescence, 
an important failsafe mechanism, was detected in HIF-/
ANXA- cells (Figure 2E). We were intrigued by the 
observation of some degree of proliferation in the HIF-/
ANXA- cells and hypothesized that the proliferating 
cell fraction had escaped the double knock-down. 
Indeed, immunoblot analysis of double KD cells after 
four weeks in culture displayed a clear ANXA1 protein 
signal, revealing that “true” double KD cells are not 
able to survive and arguing that AGS cells cannot 
compensate the simultaneous inactivation of HIF-1α and 
ANXA1 (Figure 2F). Next, we sought to confirm these 
results in a second gastric cancer cell line. As opposed 
to AGS, MKN28 cells displayed strong ANXA1 protein 
expression already under control conditions and the 
loss of HIF-1α did not affect ANXA1 protein levels 
(Supplementary Figure 6). Interestingly, inactivation of 
ANXA1 resulted in near complete death of MKN28 cells. 
Only very few cells were able to survive the lentiviral 
transduction and, when analyzed after a recovery period 
of 4 weeks, these cells turned out to be ANXA1-positive 
(Supplementary Figure 6). These results point towards 
a crucial and hitherto unrecognized role of ANXA1 for 
survival and proliferation of MKN28 cells.
Reductive carboxylation is active in AGS wild 
type cells under normal cell culture conditions
To better understand the molecular nature of the 
interaction between HIF-1α and ANXA1 in AGS cells, we 
employed pulsed stable isotope-resolved metabolomics 
(pSIRM) [26]. This method allows for dynamic 
measurements of the central carbon metabolism (CCM), 
the ultimate source of energy and building blocks essential 
for cell growth. We analyzed carbon routing and pathway 
activity within the CCM of AGS cells using U-13C6-glucose 
and U-13C5-glutamine, respectively (schematically outlined 
in Supplementary Figure 7). Incorporation of 13C-carbon 
atoms in downstream metabolites following glycolysis 
(e.g. pyruvate and lactate) and the TCA cycle (e.g. citrate) 
was monitored by GC-MS (Figures 3–5). We found 
isotopically labelled glutamate, α-ketoglutarate, succinate 
and further di-carboxylic acids towards citrate as the 
expected result of oxidative TCA cycle after labelling with 
U-13C5-glutamine (Figure 3). Thereafter, we focused on 
citrate as this metabolite is the linchpin of glycolysis, TCA 
cycle and fatty acid synthesis [27]. We detected citrate 
isotopically labelled with five 13C-carbons (Figure 4A). 
This pattern cannot be explained by oxidative TCA cycle 
metabolism as oxaloacetate cannot provide more than four 
carbon atoms (Supplementary Figure 7B). It may be a 
result of the reductive activity of isocitrate dehydrogenase 
(IDH), promoting reductive TCA cycle metabolism 
(Supplementary Figure 7C) [28–31]. The increase of 
labelled citrate quantities over time supports the idea that 
both oxidative and reductive carboxylation take place 
simultaneously in AGS cells. To analyze whether direct 
carboxylation or other pathways contribute to the observed 
mass isotopomers in citrate, we isotopically labelled 
AGS cells with 13C1-carbon dioxide (4B, Supplementary 
Figure 7D). Instead of using the gaseous form, buffer-free 
media was supplemented with 13C1 sodium bicarbonate. 
Besides the standard derivatization for GC-MS (with 
MSTFA), the derivatization agent MBTSTFA was used 
to allow for detection of the full C6 fragment of citrate 
[32]. This enabled determination of the positional 13C 
carbon incorporation into citrate (Figure 4B). The mass 
fragment 273 m/z of citrate (resulting from the MSTFA 
derivatization) contains five carbon atoms. This fragment 
revealed only minor label incorporation after 13C1 sodium 
bicarbonate tracer experiments (Figure 4B, right panel). 
However, the 375 m/z fragment, representing the full 
metabolite after MSTFA derivatization, revealed one 
labelled carbon (Figure 4B, right panel). This was 
confirmed via MBTSTFA derivatization and analysis of 
the full metabolite fragment of 459 m/z (Figure 4B, left 
panel). AGS cells incorporated a much higher yield of 
13C1-sodium bicarbonate into citrate than HEK293 cells, 
supporting the concept of direct carbon fixation in the 
TCA cycle in these cells. Our results strongly suggest the 
direct incorporation of CO2 into citrate via carboxylation 
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Figure 1: ANXA1 is a crucial mediator of HIF-1α-independent cellular proliferation. (A, B) Anchorage-dependent 
proliferation of HIF-1α-deficient (HIF-) and control (SCR) AGS and MKN28 cells under normoxia. Results shown are representative of 
three independent experiments and values represent the mean ± SEM of triplicate determinations. (C) Analysis of ANXA1 expression in 
AGS HIF- and SCR cells by immunoblot using whole cell lysates harvested at five different time points. YY-1 served as loading control. 
(D) Chromatin status of the ANXA1 promotor in AGS HIF- and SCR cells was determined by chromatin immunoprecipitation. Representative 
gels of four independent experiments are shown.
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Figure 2: Effects of combined inhibition of HIF-1α and ANXA1 on AGS cell proliferation. (A) Representative immunoblot 
analysis of ANXA1 and HIF-1α in control (SCR), HIF-1α-deficient (HIF-), ANXA1-deficient (ANXA-) and double knock-down (HIF-/
ANXA-) cells. YY-1 served as loading control. (B, C) Anchorage-dependent (B) and anchorage-independent (C) proliferation. Results 
shown are representative of three independent experiments and values represent the mean ± SEM of triplicate determinations (**P < 0.01; 
***P < 0.001). (D) Apoptosis was assayed by cleavage of caspase-3 followed by FACS analysis. Values are means ± SEM (***P < 0.001). 
(E) Senescence was quantified 96 h after cultivation by measurement of SA-β-Gal activity. Values are means ± SEM (**P < 0.01; 
***P < 0.001). (F) Representative immunoblot analysis of ANXA1 and HIF-1α. Cells were passaged regularly and grown as monolayer 
cultures under recommended culture conditions for four weeks. YY-1 served as loading control.
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Figure 3: Activity of the central carbon metabolism of AGS cells estimated by pSIRM. Glycolytic and TCA cycle activity 
of the different AGS knock-down derivatives was determined by 13C-glucose (green) and 13C-glutamine (blue) pSIRM experiments 
(n = 3). Labelled quantities of the different intermediate metabolites are shown. Abbreviations: 13BG: 1, 3 bis-phosphoglycerate; 2PG: 
2-phosphoglycerate; 3PG: 3-phosphoglycerate; AcCoA: acetyl coenzyme A; Ala: Alanine; Cit: citrate; DHAP: dihydroxyacetonate-
phosphate; F6P: fructose 6-phosphate; F16P: fructose 1, 6 bis-phosphate; Fum: fumarate; G3P: glyceraldehyde-3-phosphate; G6P: 
glucose 6-phosphate; Glut: glutamate; Icit: iso-citrate; KG: alpha-ketoglutarate; Lac: lactate; Mal: malate; Oaa: oxaloacetate; PEP: 
phosphoenolpyruvate; Pyr: pyruvate; Succ: succinate.
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Figure 4: Evidence for reductive TCA metabolism via 13C5-glutamine and 13C1-HCO3 labelling. (A) Time series pSIRM 
analysis of AGS wild type cells with U-13C5-glutamine for 15, 30 and 60 min (n = 3, n = 2 and n = 2, respectively) under normoxic 
conditions. Labelled quantities for citrate (looking at m + 3 and m + 5 mass shift of the C5 fragment; for easier recognition full metabolite 
is depicted by circles) at these three time points are shown (mean ± SD, n = 3). (B) Comparison of the derivatization agents MBTSTFA and 
MSTFA for citrate detection. Left (MBTSTFA): AGS wild type and HEK293 cells were labelled with 13C1-sodium bicarbonate for 20 min 
under normoxic conditions. Carbon fixation was observed by a mass shift on m + 1 of citrate (m/z = 459). Right (MSTFA): Same labelling 
conditions, measurement in splitless mode for improved detection of the C6-fragment. Depicted is the C5-fragment (m/z = 273) compared 
to the m + 1 of the C6-fragment (m/z = 375) of citrate. Values are means ± SD of three independent experiments.
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of α-ketoglutarate and thus the presence of a reductive 
TCA metabolism in AGS cells under normoxic conditions. 
A carboxylation of pyruvate (to form oxaloacetate by 
pyruvate carboxylase) would result in 13C incorporation 
into citrate at a different position after fusion with acetyl-
CoA (Supplementary Figure 9).
HIF-1α and ANXA1 synergistically influence 
glutamine metabolism of AGS cells
To deconstruct the molecular nature of the observed 
synthetic lethality between HIF-1α and ANXA1, we 
analyzed the corresponding knock-down cells with 
pSIRM (Figure 3 and 5). Using the labelled quantities 
of lactate as a read-out for aerobic glycolysis, HIF-/
ANXA- cells showed decreased glycolytic activity 
(Figure 3). In contrast, the labelled quantities of pyruvate 
suggested a similar overall performance of glycolysis in 
all knock-down cells. HIF-1α loss resulted in a higher 
TCA cycle activity judging from the labelled quantities 
in citrate, indicating shifted carbon routing from 
pyruvate downstream towards mitochondrial metabolism 
(Figure 5B). HIF-1 is known to repress pyruvate 
shuttling into the TCA cycle via its target gene pyruvate 
dehydrogenase kinase [33]. Knock-down of ANXA1 led 
to decreased citrate formation via acetyl-CoA as judged 
by the labelled quantities of citrate resulting from U-13C6-
glucose (Figure 5B). In addition, the activity of glutamine 
metabolism decreased upon ANXA1 inactivation judging 
the label incorporation from U-13C5-glutamine (Figure 5B). 
Strikingly, the simultaneous knock-down of both HIF-1α 
and ANXA1 revealed significantly stronger effects as both 
canonical and reductive TCA metabolism were impaired, 
arguing for a decrease of TCA cycle activity and less 
efficient glutaminolysis.
Loss of MYC underlies the proliferation defect of 
HIF-1α/ANXA1-deficient cells
Glutamine metabolism and citrate homeostasis in 
cancer cells are centrally regulated by the oncogene MYC 
[34, 35]. MYC has been described as a central driving 
force of the malignancy of AGS gastric cancer cells [36]. 
Strikingly, simultaneous inhibition of HIF-1α and ANXA1 
resulted in complete loss of MYC protein expression 
(Figure 6A). To analyse the functional importance of the 
loss of MYC for the defective proliferation and survival 
of HIF-1α/ANXA1-deficient cells, we re-introduced 
MYC via retroviral transduction (Supplementary 
Figure 10). As shown in Figure 6B, re-expression of 
MYC in HIF-/ANXA- cells resulted in a near complete 
rescue of proliferation, strongly supporting the functional 
involvement of MYC in the observed growth defect. As 
MYC represents a β-catenin target gene, we investigated 
a potential causal role of this pathway. As can be seen 
in Figure 6A, protein expression of β-catenin remained 
unchanged in all the cellular derivatives, arguing against 
a functional importance of Wnt/β-catenin in this setting.
Comparative analysis of HIF1A, ANXA1 and 
MYC expression in gastric cancer cell lines and 
primary tissues
To test the reproducibility of the above outlined 
data, we evaluated the gene expression patterns of HIF1A, 
ANXA1 and MYC in other gastric cancer cell lines (n  = 37 
[37]). Of the 37 cell lines, 29 expressed HIF1A and/or 
ANXA1 (Figure 7A). Among these HIF1A and/or ANXA1 
expressors, the majority (22/29 = 75.9%) expressed 
HIF1A and ANXA1 in a mutual exclusive manner. 
Additionally, assessment of these cell lines revealed a 
significant co-expression pattern for MYC and ANXA1 
(Figure 7B). To investigate the potential interaction 
between HIF- 1α, ANXA1 and MYC in primary gastric 
cancer, we performed a bioinformatics analysis of co-
occurrence and mutual exclusivity using a RNA-seq 
data-set from the TCGA data-base with 265 samples 
of stomach adenocarcinoma (cBioPortal [38, 39]). We 
considered that genes with an expression higher than one 
standard deviation above the mean are highly expressed 
on the respective sample and performed a pairwise 
hyper-geometric test to assess the co-occurrence and 
mutual exclusivity probability. This analysis revealed 
a tendency for mutual exclusivity between HIF1A and 
ANXA1 gene expression (odds ratio between 0 and 0.1), 
however, statistical significance was not reached (p-value 
0.783). Moreover, ANXA1 and MYC tended to co-occur 
in the same stomach adenocarcinoma samples at the gene 
expression level (odds ratio between 2 and 10). Finally, 
we performed immunohistochemistry for HIF-1α and 
ANXA1 on a tissue microarray comprising 397 samples 
of human gastric adenocarcinoma. Given the function 
of HIF-1 as a transcription factor, only nuclear signals 
were quantified and analyzed, while ANXA1 protein 
has been described to exert functions at various cellular 
locations, e.g. cell membrane, cytoplasm and nucleus 
(Supplementary Figure 11). Interestingly, 80.4% of HIF-
1α-positive gastric cancers were negative for ANXA1, 
further supporting the notion of mutual exclusivity. Taken 
together, the comparative analysis of HIF-1α, ANXA1 
and MYC expression in human gastric cancer samples 
confirmed the in vitro data, further indicating a potential 
functional association between HIF-1α, ANXA1 and 
MYC in this tumor entity.
DISCUSSION
Drug resistance is a pivotal obstacle in clinical 
cancer care. While a plethora of molecular-targeted drugs 
was newly approved for cancer therapy in recent years, 
this did not translate into improved overall survival for 
the majority of cancer entities. It is widely assumed that 
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Figure 5: Reductive carboxylation is reduced in HIF-/ANXA- AGS cells. (A) Schematic representation of the different mass 
isotopomers of citrate and the corresponding origin via the different labelling substrates U-13C6-glucose and U-
13C5-glutamine. Three 
different mass isotopomers of citrate are the result of oxidative (ox) and reductive (red) carboxylation ( ,   and   ). 
(B) Shown are the corresponding labelled quantities of the detectable C5-fragment of citrate (n = 3; mean ± SD; *P < 0.05; **P < 0.01; 
***P  < 0.001)) for control (scr) and the different knock-down AGS cells.
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secondary resistance underlies the suboptimal efficacy of 
most targeted therapeutics and that combined inhibition of 
cancer-driving pathways represents an attractive approach 
to circumvent the emergence of drug resistance [2, 3]. 
Identification of pathways and molecules that qualify as 
targets for an effective combination therapy is therefore of 
paramount importance. Our data support the notion that 
the stable inhibition of a given cancer-driving factor in an 
established cancer cell line can serve as a valuable tool 
to identify targets for effective combinatorial approaches.
HIF-1 was originally described as the principle 
mediator of cellular adaptation to hypoxia [6]. The 
majority of cancer cell lines and experimental tumor 
models depends on HIF-1 for growth and systemic 
spread, resulting in the general appreciation of HIF- 1 
as an oncoprotein and an attractive target for cancer 
therapy [40]. Given the rapid emergence of resistance 
against molecular-targeted drugs, we hypothesized that 
drug resistance will also occur during treatment with 
HIF-1 inhibiting agents and sought to characterize the 
underlying molecular mechanisms. To achieve this, we 
took advantage of a previously established shRNA-based 
stable inhibition of HIF-1α in a number of cancer cell 
lines [15, 20]. Strikingly, stable inhibition of HIF- 1α 
did not interfere with cellular proliferation in the 
majority of analyzed cell lines. This rather unexpected 
observation could either mean that HIF-1 is not essential 
for malignant growth of gastric cancer cells or that the 
cells were able to compensate the stable loss of HIF-1α 
over time, enabling them to thrive in a HIF-1-independent 
fashion. Via transcriptome analyses we were able to 
identify a group of genes with enhanced expression 
upon HIF- 1α loss. Repression of target gene activity 
by HIF-1 has been reported and can occur via binding 
Figure 6: Contribution of MYC to the growth defect in HIF-1α/ANXA1-deficient cells. (A) Representative immunoblot 
analysis of MYC and β-catenin in control (SCR), HIF-1α-deficient (HIF-), ANXA1-deficient (ANXA-) and double knock-down (HIF-/
ANXA-) AGS cells. YY-1 served as loading control. (B) Re-expression of MYC was achieved by transduction with retroviruses containing 
human MYC and anchorage-dependent proliferation was analyzed 14 days post transduction. Results shown are representative of three 
independent experiments and values represent the mean ± SEM of triplicate determinations (***P < 0.001).
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Figure 7: Comparative analysis of HIF1A, ANXA1 and MYC expression in gastric cancer cell lines. (A) A Venn diagram to 
illustrate the cell line samples with overlap of expression for HIF1A and/or ANXA1 and/or MYC. As shown, four cell lines, namely CLS145, 
Hs746T, SNU719 and YCC6, expressed all 3 genes (i.e. HIF1A, ANXA1 and MYC). Generally, HIF1A and/or ANXA1 expressors show 
expression mutual exclusivity. (B) Heatmap (left) shows results of hierarchical clustering of HIF1A, MYC and ANXA1 gene expression 
across the 37 cell line samples. In general, apart from co-expression pattern seen for MYC and ANXA1, most of the gene-pairs appeared to 
have patterns of expression mutual exclusivity. A pairs-plot (middle) and a correlation-matrix heatmap (right) further support these findings 
i.e. a significant correlation (p < 0.05) for co-expression was found only for MYC and ANXA1.
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of HIF-1 to a so-called “reverse HRE” [41, 42]. Hence, 
enhanced gene expression in HIF-1α-deficient cells could 
be explained by active repression of these genes when 
HIF-1 is present. We hypothesized, however, that some of 
the genes with enhanced expression might not be actively 
repressed in WT cells, but rather get activated as part of 
the cellular adaptation process to compensate for the loss 
of HIF-1α [43]. These genes would therefore be crucial 
for HIF-1-independent survival and could represent 
interesting targets for a combination therapy with HIF-1 
inhibitors. To support our hypothesis we analysed the role 
of annexin A1 (ANXA1) for growth of HIF-1α-deficient 
cells. ANXA1 is a member of the annexin protein family, 
named after their ability to annex to phospholipids in 
the cell membrane [44]. ANXA1 is best known for its 
anti-inflammatory role and is considered to be a therapy 
target for chronic inflammatory conditions [45]. We chose 
ANXA1 for further analysis due to its suppressive action 
on the NF-kB pathway [23]. As reported previously by us, 
the NF-kB pathway is strongly repressed in gastric cancer 
cells upon stable loss of HIF-1α [21]. Studies based on 
cDNA microarray analyses reported differentiation-
dependent expression of ANXA1 in human gastric cancer 
with higher expression in diffuse-type than in intestinal-
type gastric cancers [46, 47]. Immunohistochemistry 
data obtained with tissue microarrays reported loss 
of ANXA1 in 64% of primary gastric cancers and 
86% of lymph node metastases, arguing for a tumor-
suppressive function of ANXA1 in gastric cancer [48]. 
Our data point towards a crucial and hitherto unreported 
role of ANXA1: Functional compensation of stable 
HIF-1α loss (Supplementary Figure 12). Numerous 
international research groups, including ourselves, 
have published data pointing towards a crucial pro-
tumorigenic role of HIF-1 in gastric cancer [15, 21, 49]. 
Our data demonstrate that gastric cancer cells are able 
to functionally compensate the loss of HIF-1α, arguing 
for the emergence of resistance during a potential therapy 
of gastric cancer with HIF-1-inhibiting agents. We 
could show that simultaneous inhibition of HIF-1α and 
ANXA1 leads to robust and non compensable cell death, 
arguing for a combination therapy of HIF-1 and ANXA1 
inhibitors for gastric cancer. In this setting, the anti-
inflammatory function of ANXA1 needs to be regarded: 
ANXA1 inhibiting substances might result in enhanced 
inflammatory activity, potentially causing undesirable 
side effects. One possible strategy to avoid this scenario 
is to target the nuclear function of ANXA1. As outlined 
above, the enhanced ANXA1 protein in HIF-1α-deficient 
cells is almost exclusively found in the nucleus. The 
nuclear function of ANXA1 differs from cell membrane-
bound ANXA1, the latter being mediated by binding to 
its specific membrane receptor ALXR [44], the former 
by direct binding to DNA. Hence, specific inhibitors of 
nuclear ANXA1 activity would be ideal combination 
partners for pharmaceutical HIF-1 inhibitors without the 
risk of enhanced inflammation.
As HIF-1 is known to regulate various metabolic 
enzymes, we explored the nature of defective proliferation 
in HIF-1α/ANXA1-deficient cells using pulsed stable 
isotope-resolved metabolomics (pSIRM). We applied this 
technology as a diagnostic tool and analysed the dynamics 
of glycolysis and glutaminolysis using 13C-labelled 
substrates at in-stationary isotope incorporation 
states. This approach led to the observation that both 
oxidative and reductive carboxylation (RC) take place 
simultaneously in AGS wildtype cells. The presence of RC 
was rather unexpected as our experiments were performed 
under normoxic conditions and RC is usually favoured 
under conditions of hypoxia [50]. Thus far, normoxic 
RC has only been reported in cells with a mutated von 
Hippel-Lindau tumor suppressor gene or defective 
mitochondria [30, 31]. Of note, HIF-1 was identified as 
the main regulator of RC under both hypoxic and VHL-
defective conditions [51, 52]. Against this background it is 
important to note that AGS cells display functional HIF-1 
under normoxic conditions, a phenomenon seen in various 
cancer cell lines and mainly attributable to activation of 
oncogenes (e.g. ras), inactivation of tumor suppressor 
genes (e.g. vhl), reactive oxygen species or metabolite-
mediated PHD inhibition [12]. Hence, normoxic RC in 
AGS cells could principally be mediated by HIF-1 activity. 
However, as stable inactivation of HIF-1a in AGS cells 
did not result in significant reduction of RC, HIF-1 seems 
dispensable in this setting and the regulatory nature of RC 
in these cells remains elusive.
Therapy resistance – either primary or secondary- 
results in therapy failure, which in the clinical setting 
almost always means cancer progression and decease 
of the affected patient. It is therefore not surprising 
that therapy resistance and the governing molecular 
mechanisms are usually discussed as phenomena that 
need to be either avoided or tackled. While this is certainly 
true and the efforts to better characterize the molecular 
nature of therapy resistance are undeniably justified, 
our data point towards the appreciation of therapy 
resistance as a door opener to innovative and, eventually, 
more efficient forms of cancer therapy. The adaptation 
processes that enable the survival of neoplastic cells in 
response to antiproliferative therapies result in usage of 
alternative pathways to maintain the malignant phenotype. 
We propose to exploit the molecular mechanisms of this 
adaptation to identify new therapy targets. Our results 
demonstrate the applicability of this approach, starting 
with the analysis of cell lines and validating the results 
with RNA and protein expression data from a large 
collection of human cancer samples. 
Taken together, we believe that stable HIF-1α-
deficient tumor cells represent precious experimental 
tools as they potentially mirror molecular events that 
might confer resistance of human tumors towards HIF- 1 
inhibitors. Our work applying “omics-“analyses to such 
cells showed robust activation of factors centrally involved 
in the regulation of apoptosis, survival, cell cycle and 
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redox balance upon inactivation of HIF-1α [43]. We 
believe that this experimental approach will lead to the 
identification of multiple pathways whose inhibition holds 
the potential to enhance the antiproliferative efficacy of 
HIF-1 inhibitors. In addition, this strategy should prove 
valuable to deconstruct resistance to other cancer-driving 
factors, e.g. activated oncogenes and tyrosine kinases, as 
the basic methodology is applicable to any target of choice.
MATERIALS AND METHODS
Ethics statement
Investigation has been conducted in accordance with 
the ethical standards and according to the Declaration of 
Helsinki and according to national and international 
guidelines and has been approved by the authors’ 
institutional review board.
Cell lines and culture conditions
The human gastric cancer cell line AGS (CRL-1739, 
ATCC, Rockville, USA) and MKN28 (Riken, Ibaraki, 
Japan) were grown as monolayer cultures in recommended 
medium. Generation of AGS and MKN28 cells stably 
expressing either shRNA specifically targeting HIF-1α 
(HIF-) or unspecific control shRNA (scrambled, “SCR”) 
was published previously [15, 20]. To stably knock-down 
annexin A1 (ANXA1), AGS cells were transduced with 
two lentiviruses containing different shRNA sequences 
against human ANXA1 (MISSION® shRNA lentiviral 
transduction particles; Sigma-Aldrich, Deisenhofen, 
Germany). AGS cells stably re-expressing MYC were 
generated by double transduction with retroviruses 
containing human MYC [53].
Cell growth assay
For determination of anchorage-dependent cell 
growth, 3 × 104 cells were seeded in triplicate into 24- well 
plates. Cells were trypsinized and counted every 24 h 
using a hemocytometer. Media were not changed for 
the duration of the experiment. Anchorage-independent 
growth was assessed by human tumor clonogenic assay as 
described before [54].
Tumor xenograft growth
Female NOD/SCID mice (n = 3) purchased from 
Taconic (Denmark) were inoculated at day 0 with 107 cells 
of the MKN28 HIF- or SCR cells. Tumor growth was 
monitored twice per week by caliper measurements and 
calculation of tumor volumes (TV). The animal experiments 
were approved by the local ethical committee (LaGeSo 
Berlin) and performed according to the “Guidelines for the 
welfare and use of animals in cancer research” [55].
Determination of cell cycle distribution, 
proliferation and apoptosis by flow cytometry
Cell cycle distribution including the pre-G1 fraction 
was determined from DNA histograms as described 
before [54]. Apoptosis was quantified from detection of 
active, cleaved caspase-3 by flow cytometry using an 
Alexa Fluor® 488-conjugated antibody (Cell Signaling 
Technology, Danvers, Massachusetts, USA) according to 
the manufacturer’s protocol. Cell proliferation and the rate 
of DNA synthesis were determined by flow cytometry on 
AGS cells labelled with anti-BrdU antibody (AbD Serotec, 
Puchheim, Germany) and propidium iodide (PI, Sigma-
Aldrich) according to the manufacturer’s protocol. Briefly, 
cells were pulse labelled with 10 µM BrdU (Sigma-
Aldrich) for 60 min, acid-treated and stained with an 
anti-BrdU and a secondary APC-conjugated antibody for 
determination of DNA synthesis and with 20 µg/ml PI for 
determination of total DNA content.
Quantification of senescence
Senescence-associated β-galactosidase staining 
was performed according to the manufacturer‘s protocol 
(Sigma-Aldrich).
Immunoblot analysis
Whole cell lysates or nuclear protein extracts were 
prepared as previously described [54, 56], then resolved 
on a sodium dodecyl sulfate-polyacrylamide gel, and 
transferred to a nitrocellulose membrane (Amersham 
Biosciences, Freiburg, Germany). Blots were probed 
with antibodies against actin (Sigma-Aldrich), annexin 
A1 (BD Biosciences, Heidelberg, Germany), β-catenin 
(BD Biosciences), MYC (Santa Cruz Biotechnology, 
Santa Cruz, USA), HIF-1α (Cayman Chemical, Ann 
Arbor, USA), HIF-2α (Novus Biologicals, Littleton, 
USA) and YY-1 (Santa Cruz Biotechnology). Secondary 
antibodies were conjugated to horseradish peroxidase 
(Dianova, Hamburg, Germany) and peroxidase 
activity was visualized using the Western Lightning™ 
Chemiluminescence Reagent Plus (Perkin Elmer Life 
Sciences, Boston, Massachusetts, USA).
Immunocytochemical detection of annexin A1 
Cells grown onto sterile coverslips were fixed in 
4% paraformaldehyde for 20 min at RT, washed twice 
with PBS and permeabilized in 0.1% Triton X-100/
PBS for 10 min. Following permeabilization, cells were 
washed twice with PBS, blocked for 30 min in PBS with 
2% nonfat dried milk, washed twice again and were then 
incubated with an antibody to human annexin A1 in 
0.1% BSA/PBS at RT. Cells were washed four times in 
PBS before incubation with a Cy3-conjugated antibody 
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followed by two additional washes with PBS and final 
fixation in ethanol. Cells were mounted in Elvanol and 
immunofluorescence was evaluated on a confocal laser 
scanning microscope LSM510 (Zeiss, Jena, Germany).
Chromatin immunoprecipitation (ChIP)
ChIP analysis was conducted in cells grown to 
confluency. For crosslinking, cells were incubated with 
1% formaldehyde/PBS for 1 min at RT and the reaction 
was stopped by the addition of ice-cold 0.125 M glycin/
PBS. Cells were washed twice with PBS and then 
rapidly collected by scraping in PBS with subsequent 
centrifugation. Cell pellets were resuspended in RIPA 
buffer [10 mM Tris (pH 7.5), 150 mM NaCl, 1% NP- 40, 
1% desoxycholic acid, 0.1% SDS, 1 mM EDTA] 
supplemented with protease inhibitors (complete EDTA-
free protease inhibitor cocktail tablets; Roche) and the 
chromatin was sheared by sonication. Lysates were 
clarified by centrifugation. Immunoprecipitations were 
performed using anti-mRNA polymerase II (Pol II, Santa 
Cruz Biotechnology), anti-acetyl-Histone H4 (Merck 
Millipore, Billerica, USA), anti-H3K4me3 (abcam, 
Cambridge, United Kingdom), anti-p300 (Santa Cruz 
Biotechnology) and a rabbit control IgG antibody (abcam) 
at 4°C overnight. Immune complexes were captured by 
addition of 40 µl of protein A/G agarose slurry for 2 h. 
Following pull down the agarose beads were subsequently 
washed twice with RIPA buffer, followed by one wash-
step each using high-salt buffer [2 M NaCl, 10 mM Tris 
(pH 7.5), 1% NP-40, 0.5% desoxycholic acid, 1 mM 
EDTA], RIPA buffer and TE buffer [10 mM Tris (pH 
7.5), 1 mM EDTA]. Immune complexes were extracted 
by addition of 55 µl elution buffer (TE buffer containing 
1% SDS) and shaking for 20 min at 1,200 rpm (30°C). 
The crosslinking was reversed by incubation for 30 min at 
37°C in the presence of RNase (1 µg/20 µl, AppliChem), 
followed by proteinase K treatment (1 µg/2.05 µl, 
AppliChem, Darmstadt, Germany) for 6 h at 37°C and a 
final incubation for 6 h at 65°C. DNA was purified using 
the PCR purification kit (Qiagen). Purified ChIP DNA 
as well as input DNA was amplified by PCR using PAN 
Hotstart DNA Polymerase (PAN Biotech, Aidenbach, 
Germany). PCR products were separated by agarose 
gel electrophoresis and detected by ethidium bromide 
staining. Primer sequences are supplied in Table E1.
Quantitative real-time PCR analysis
Total cellular RNA was isolated using the RNeasy 
Mini Kit according to the manufacturer’s protocol 
(Qiagen) and first strand cDNA was synthesized with 
an oligo (dT) primer and a SuperScript™ First Strand 
Synthesis System (Invitrogen, Rockville, Maryland, 
USA). Quantitative real-time PCR analysis was 
conducted by using TaqMan PCR Universal Mastermix 
(for β-actin) or SYBR GREEN PCR Master Mix (for 
Annexin A1; Applied Biosystems, Darmstadt, Germany). 
Quantification was performed by the comparative ∆CT 
method normalizing CT-values to β-actin.
Global gene expression analysis
Total RNA was quantified by a Nanodrop 2000 
spectrophotometer and quality checked using a total RNA 
6000 nano chip on a 2100 Agilent Bioanalyzer (Agilent 
Technologies, Böblingen, Germany). All samples were of 
high quality with RNA integrity numbers (RIN) of 9.9 or 
10. On a scala from 1 to 10, a RIN of 10 represents the 
highest RNA integrity. For array hybridization, 500 ng of 
RNA were used for the synthesis of biotinylated cRNA 
employing a linear amplification kit (Ambion, Darmstadt, 
Germany). The biotinylated cRNA was then hybridized 
on a HumanHT-12 v4 Expression BeadChip (Illumina, 
San Diego, USA). Hybridization, washing, detection with 
Cy3-strepatvidin and scanning were performed on the 
Illumina BeadStation 500 platform (Illumina) according 
to the manufacturer’s instructions. Expression data were 
normalized using RMA and filtered using the beadarray 
package in the statistical language R [57]. Different array 
versions for the biological replicates were compared 
based on probe IDs common to all three independent 
experiments. Genes that displayed consistent expression 
below the 50% expression quantile were discarded. 
Expression data from technical replicates were averaged 
for further analysis. To account for the dynamic variation 
within the signal range of the arrays, fold changes of 
sample to control were z-transformed using an error model 
as described previously [58]. We then defined those genes 
as significantly regulated where the absolute z-value was 
consistently among the top 10% in each experiment, 
and had consistent sign of regulation. Using 1000 triple 
random draws with replacement, we estimated that the 
FDR of this approach is 0.1. GO and Pathway analysis 
were conducted using WebGestalt [59].
13C tracer experiments
For tracer experiments, culture media was refreshed 
4 h before cell harvest in order to avoid nutrient depletion. 
Glucose- and glutamine-free medium (DMEM, Genaxxon 
Bioscience, Ulm, Germany) was supplemented with the 
corresponding amount of lysine (146 mg/L) and arginine 




U-13C5-glutamine. For the U-
13C1-sodium bicarbonate 
tracer experiment, glucose- and sodium bicarbonate-free 
media (XF Assay Medium Modified DMEM, Seahorse 
Bioscience, Copenhagen, Denmark) was supplemented 
with U-13C1-sodium bicarbonate (3.7 g/L), glucose 
(4.5 g/L) and glutamine (6 mM). U-13C6-glucose was 
purchased from Campro Scientific (Berlin, Germany), 
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U-13C5-glutamine from Cambridge Isotope Laboratories 
(Andover, USA) and U-13C1-sodium bicarbonate from 
Isotec™ (Miamisburg, USA).
Metabolite extraction and pulsed stable isotopic 
resolved metabolomics
All tracer experiments were performed in triplicate 
and a labelling period of 7 min for U-13C6-glucose and 
15 min for U-13C5-glutamine was used (exceptions stated 
otherwise). After addition of tracer medium, cells were 
rapidly washed with a washing solution (5 mM HEPES, 
3 mM KCl and 140 mM NaCl supplemented with the 
corresponding isotopes of 13C-glucose and 13C-glutamine). 
Cellular metabolism was quenched by addition of 5 mL 
ice-cold 50% methanol containing cinnamic acid as an 
internal standard (4 µg/ml). Cells were transferred to 
a reaction tube containing chloroform (total of 0.2 mL 
chloroform per 1.0 mL 50% methanol), vortexed, snap-
frozen in liquid nitrogen and either stored at –80°C or 
thawed and shaken for at least 1 h at 750 rpm at 4°C. 
Phase separation was achieved by centrifuging at 7197 g 
for 10 min at room temperature. Polar and apolar phases 
were dried overnight in a vacuum concentrator (RVC 2–33 
CD Plus coupled to a freeze dryer ALPHA 2–4 LD Plus, 
Christ, Germany). Tracer experiments with U-13C1-sodium 
bicarbonate were performed applying 20 min labelling 
time in AGS and HEK293 cells.
Derivatization and GC/MS measurements
After metabolite extraction in 20% methanol and 
shaking at RT for 45 min, samples were dried overnight 
and prepared for GC-MS analysis as described [26]. 
Samples were analyzed in technical duplicates. The 
GC-MS chromatograms were processed with the 
ChromaTOF software (Version 4.42, LECO). A modified 
Golm metabolome database (GMD; http://gmd.mpimp-
golm.mpg.de) version was used to identify substances 
with respect to spectra similarity and identical retention 
index. In addition, peaks were manually checked in 
comparison to an in-house identification mix containing 
the metabolites of interest. Data matrices for relative 
quantification and isotope patterns were extracted from the 
mass spectra exported files using the MetMax software 
[60]. The derivatization agent MBTSTFA + 1% TBDMCS 
(Sigma-Aldrich) was used as described [32] except for 
the sonication at the beginning. Samples were shaken at 
750 rpm and the same n-alkane-standard was added to 
MBTSTFA + 1% TBDMCS. As identification standard, 
10 µg of pure citrate were processed in the same way to 
obtain retention time and peak information.
Data analysis of metabolomics
Each MetMax-extracted metabolite area information 
was normalized to the internal standard cinnamic acid 
before further statistical analysis was performed either 
in R [61] and RStudio (Version 0.96) with different 
packages as ggplot2 (Version 0.9.3), reshape2 (Version 
1.2.2), stringr (Version 0.6.2) and plyr (Version 1.8) or in 
Microsoft Excel. For calculation of the label incorporation, 
MetMax was used to extract the corresponding metabolite 
intensities for defined isotopic mass ranges in combination 
with the retention index. Intensities of one identification 
standard were used as a reference for „unlabeled“ 
metabolites (reflecting the natural 13C abundance) in order 
to estimate the label incorporation into the metabolite of 
interest as described previously [62].
Gene expression analysis of gastric cancer cell 
lines
Expression data from 37 gastric cancer cell lines 
(GSE22183) were normalized (‘RMA’ function; ‘affy’ 
package R v.3.1.0) and log2 transformed. Summarization 
was done by taking the median log2 expression of same-
gene probes. To obtain “up-regulated” and “down-
regulated” samples for the respective genes, the median 
gene profile was subtracted from the summarized gene 
expression for each sample. To examine potential co-
expression patterns and/or patterns of expression mutual 
exclusivity, log2 gene expression for HIF1A, MYC and 
ANXA1 across the cell lines were z-score-transformed 
and clustered using a euclidean-distance-based 
hierarchical clustering approach. Pearson’s correlation 
analyses were also performed. Finally, hypothesis 
testing was carried out (cor.test function; ‘stats’ package 
R v.3.1.0) so as to estimate the association between 
paired genes and compute a test of the correlation value 
being zero.
Immunohistochemistry
Immunohistochemical detection and analysis of 
HIF-1α and was performed according to our previously 
published protocol [15]. Annexin A1 was detected with 
a mouse monoclonal antibody (BD Biosciences) at a 
dilution of 1:100 after antigen retrieval consisting of 5 
minutes heating in a pressure cooker. Tissue microarrays 
were constructed from 397 human gastric cancer samples 
using the Beecher manual TMA machine sampling from 
an area with the highest tumor cell density using three 
0.6 mm tumor cores per case. All patients underwent 
surgical resection at the Leeds General Infirmary, UK, 
between 1968 and 2004. None of the patients received pre-
operative chemotherapy or chemoradiotherapy.
Statistical analysis
Shown are means ± SEM of at least three 
independent experiments. Statistical analysis was 
performed by unpaired Student’s t test. Differences were 
considered statistically significant at P < 0.05.
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Data deposition
The microarray data from this publication have been 
submitted to the NCBI Gene Expression Omnibus (GEO) 
database (www.ncbi.nlm.nih.gov/geo) and assigned the 
identifier GSE57200.
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